UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **June 24, 2025**

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

001-35023	**26-2797813**
(Commission File Number)	*(IRS Employer Identification No.)*

11750 Sorrento Valley Road, Suite 200
San Diego, California 92121
(Address of principal executive offices and zip code)

(979) 446-0027
(Registrant's telephone number including area code)

N/A
(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01. Other Events.

The Company has updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation of iBio, Inc., dated June 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 24, 2025

IBIO, INC.

By: /s/ Marc A. Banjak
Name: Marc A. Banjak
Title: Chief Legal Officer

Exhibit 99.1


iBio
Breakthrough Antibodies for Obesity and Cardiometabolic Diseases
Corporate Presentation
June 2025

Forward looking statements

Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and includes statements regarding near term catalysts. While iBio, Inc., a Delaware corporation (including its consolidated subsidiaries, "iBio," the "Company," "we," "us" or "our") believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to attain license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its Nasdaq Stock Market listing, and the other factors discussed in the Company's most recent Annual Report on Form 10-K and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

Revolution Sparked a New Era in Obesity Treatment

Evolution Will Define Its Future

Incretin Class Agonists Have Revolutionized Obesity Treatment

>10% of American adults have taken a GLP-1[1]

Interventional weight loss previously only achievable via surgery

Attention is Shifting to Therapies That Build on That Foundation

Durability of weight loss

Lean mass preservation and fat-specific weight loss

Improved tolerability and convenience

1. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

The GLP-1 Revolution Unlocked Possibility — We Aim to Drive the Evolution

"For every 1 kg weight lost… 0.32 kg lean tissue was lost and for every 1 kg weight regained…, only 0.08 kg lean tissue was regained"[1]

"Compared to (control) group, the [weight loss/regain] group had a statistically significant 39% increased risk of a frailty fracture"[2]



iBio's Strategy to Redefine Obesity Care with Next-Generation Antibody Therapies

Address Challenges With Current GLP-1 Drugs

- **Muscle** mass **loss**
- **Side effects** leading to discontinuation
- Inconvenient **dosing frequency**
- Room for **high quality** weight loss

Focus on Highly Validated Targets

- **Preserve and build muscle mass**
- **Fat-specific** weight reduction
- Targeting both sides of the equation, **calorie intake** and **energy expenditure**

iBio's Platform Fuels a High-Value Pipeline

- Tackling **complex**, hard to drug targets
- Optimizing **function** and **developability** simultaneously
- Rapidly optimizing **multi-specifics**

Next Generation Antibodies for Obesity Targeting Key Gaps in Current Care



Corporate Highlights

Lead Programs

- **IBIO-600**: Long-acting myostatin antibody
- **IBIO-610**: First-in-class Activin E antibody

Pipeline Expansion

- **3** early-stage high novelty programs and **2** partnered programs
- Discovery to development candidate **in as little as 7 months**
- AI engine delivers **precisely targeted antibodies** with exceptional developability

Near Term Catalyst

IBIO-600 **IND/IND** equivalent filing by 1Q2026*

IBIO-600 **Phase 1** initiated 2Q2026*

IBIO-610 **IND/IND** equivalent filing by end of 2026*

** Financing Dependent*

iBio's Strategy in Motion: Rapidly Advancing Next-Gen Treatments Beyond First-Gen Obesity Drugs




IBIO-600
Long-Acting Anti-Myostatin
Antibody

Strengthening the Weight Loss Journey: Myostatin Inhibition to Preserve Muscle Mass

We are developing Myostatin inhibitors to **preserve and increase muscle mass**, **complementary to** current treatments

Why We Target Myostatin

- **Incretin drugs** reduce caloric intake, causing **weight loss in both fat and muscle**
- Myostatin is a **highly validated key negative regulator** of muscle mass[1]
- Inhibition of Myostatin function drives significant **muscle growth without** apparent **adverse health effects**
- Beyond its effects on muscle, Myostatin plays a role in the **regulation of total body fat mass**[2]

Binding of Myostatin to cells leads to **muscle atrophy**



Blocking of Myostatin leads to **muscle growth**



1. Schuelke M. (2004). New England Journal of Medicine 350(2682–2688).
2. Deng, B. (2017). Nutrition and Metabolism, 14(29).

IBIO-600: A Differentiated Long Acting Anti-Myostatin Program

Improved Pharmacokinetics	Potential best-in-class PK based on allometric scaling and dosing regimen suggests **2-4x improved PK** over competitors
Dual Mechanism	Dual myostatin and GDF11 blockade has potential for **improved lean mass preservation** and **fat mass reduction**
Enhanced Manufacturability	Optimized for **high expression** and **stability** to enable efficient manufacturing process
Coformulation Optionality	**High formulation** concentration to **lower injection** volume
Convenience	Administration as infrequent as **twice a year**

IBIO-600 Enhances Muscle Differentiation in Human Myoblasts by Targeting the Two Growth Suppressors Myostatin and GDF11

The **human Myoblast differentiation** model is **highly predictive** of **muscle growth** in humans





IBIO-600 Fc Engineering Drives Extended Half-Life in Obese NHPs

12 Week Pharmacokinetics Data[1]



Study Details:
- *Obese, aged NHPs*
- *Monthly DEXA scan for body composition*
- *Periodic PK sampling*

IBIO-600 Fc Engineering Results in Enhanced FcRn Binding

Clone	Fc	Fold increase over standard IgG
IBIO-600 FAB	Standard IgG4	**1.0**
IBIO-600	Engineered IgG4	**16.5**

IBIO-600 Demonstrates Extended Half-Life in NHPs

Dose	$t_{1/2}$ (days)
5 mg/kg, I.V.	**52.4**

Study Design:
- *N=3 per group*
- *5mg/kg single I.V. dose*

1. *Linear elimination phase used to estimate half-life with simple linear model Data on file*

IBIO-600 Dose Modeling From Human Muscle Cells and Monkey PK Predicts Low Dose Requirements to Block Myostatin for Extended Durations

IBIO-600 Blocks the Effect of Myostatin on Human Muscle Cells

IC_{90} (90% inhibition level) = 1.2 ug/mL (7.97 nM)



At 5 mg/kg Dose, IBIO-600 Achieves >90% Myostatin Inhibition for 8 Weeks

IC_{90} in muscle (1.2 ug/mL) translates to 30 ug/ml plasma levels assuming mAb Muscle/Plasma Ratio ~4%



Allometric Scaling Predicts Potentially Extended Half-Life for IBIO-600, Enabling Infrequent Dosing and Prolonged Myostatin Inhibition

Allometric Scaling Model for Half-Life Extended Antibodies[1]

Generic allometric scaling model for antibodies[2]



$$T_{1/2Human} = T_{1/2NHP} \times \left[\frac{\text{Human Body Weight}}{\text{NHP Body Weight}}\right]^{0.15}$$

Measured NHP and Predicted Human Half-Life of IBIO-600

Dose	NHP $t_{1/2}$ (actual)	Human $t_{1/2}$ (predicted)[1,2]
5 mg/kg, I.V.	52.4	**74-130 days**

1 https://pmc.ncbi.nlm.nih.gov/articles/PMC9709760/#CR37
2 https://www.jstage.jst.go.jp/article/bpb/43/5/43_b19-01042/_html/-char/en
Data on File

PK Modeling Suggests IBIO-600 Can Be Dosed Twice-Yearly, Quarterly, or Co-Formulated With Weekly GLP-1s

Modeling Assumptions:	150 mg/mL formulation	$T_{1/2}$ = 90 days	Bioavailability = 70%

Twice Per Year Dosing
(4 x 2 mL s.c.)



Quarterly Dosing
(2 x 2 mL s.c. or 1 x 2 mL s.c. + 2 mL loading dose)



Co-Dosing With Weekly GLP-1
(1 x 0.167 mL s.c. injections)



Single Clinically Relevant Low Dose of IBIO-600 Drives Sustained Muscle Gain and Fat Loss in Aged, Obese Non-Human Primates

Percent Increase in Lean Mass

Single 5 mg/kg Dose



Percent Decrease in Fat Mass

Single 5 mg/kg Dose



IBIO-600 Summary and Next Steps

IBIO-600 Highlights

- ✓ **NHP studies show potential best-in-class half-life,** may enable dosing as infrequent as twice a year
- ✓ **Differentiated profile (myostatin and GDF11 blockade)** drives robust lean mass growth and fat loss in NHPs
- ✓ **High expression titers and stability** at high concentrations expect to enable efficient, scalable manufacturing

Status and Planned Development

- **IND-enabling studies** (CMC manufacturing and GLP toxicology) ongoing
- **Initial regulatory filing** (IND or equivalent) planned for Q1 2026*
- **First patient dosed** anticipated in 2Q 2026*


IBIO-610
Anti-Activin E Antibody

IBIO-610 Targets Activin E to Drive Targeted Fat Loss and Maintains Weight Reduction After GLP-1 Discontinuation

Why We Target Activin E

- Activin E is a Hepatokine, produced in the liver and a member of the TGFβ family
- Activin E and its receptor are highly genetically validated
- Genetic loss of function decreases adiposity and risk for Diabetes / Cardiovascular Disease (CVD)
- **2 RNA targeting molecules provide preclinical pharmacological validation**
- Challenge to produce active recombinant Activin E until recently has proven to be extremely difficult for antibody discovery



IBIO-610 Breaks New Ground as the Known First-in-Class Antibody Targeting Activin E

Class-Leading Pathway Targeting	Antagonist antibody offers potential for **greater Activin E inhibition** than siRNA-based knockdown approaches
Dual Mechanism	Pre-clinical studies demonstrate weight loss with **no impact on lean mass**
Synergistic to GLP-1 Receptor Agonists	**Synergistic weight loss** with appetite reducing drugs like GLP-1 or Amylin
Weight Lowering and Maintenance Therapy	**Stand-alone** weight loss intervention and weight loss maintenance post GLP-1 or Amylin treatment

IBIO-610 Exhibits High-Affinity Binding and Potent Inhibition of Activin E Signaling in Engineered and Primary Human Fat Cells

Target Protein Binding Assay



Reporter Cell Line Functional Assay



Primary Human Adipocyte Assay



IBIO-610 Induces Fat-Selective Weight Loss in Diet-Induced Obese Mice

Study Design

Weight Loss = 8.9%



Fat Loss = 26%



No Lean Mass Loss



*Non-responder outlier mice removed, IBIO-610 mouse surrogate used. 10 mg/kg, BIW dosing. DIO mice Data on file

IBIO-610 Synergizes with GLP-1 Through a Distinct, Non-Appetite-Based Mechanism

Study Design



Synergistic Weight Loss



No Additional Appetite Suppression



Visceral Fat Reduction



IBIO-610 Prevents Weight Regain Following GLP-1 Treatment in Obese Mice

Significant Prevention of Weight Regain



Fat-Specific Effect



Study Design




The Next Wave of iBio Innovation
Early Pre-Clinical Programs

Harnessing Amylin Biology with Precision Targeting: iBio's Engineered Antibody Agonist Approach

Why We Target Amylin

- **Validated metabolic hormone** that promotes satiety, slows gastric emptying, and reduces postprandial glucose excursions
- Clinical studies with amylin analogs confirm efficacy in weight loss, but **peptide-based approaches may be sub-optimal** (dosing, tolerability, manufacturability)
- Amylin receptor-selective antibody agonists could provide a differentiated profile, with **potential for longer duration of action and reduced side effects** alone or in combination therapy

Selective amylin receptor agonists (rather than DACRAs*) have potential as a more precisely targeted obesity intervention



1. J Gingell, J. *et al.* An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. *Cell Discov* 2, 16012 (2016).

*Dual Amylin and Calcitonin Receptor Agonists
**Selective Amylin Receptor Agonist

Combined Myostatin and Activin A Antagonism

Synergistic Effect on Muscle Growth and Potential Treatment for Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)

We are developing bispecific **co-inhibitors of Myostatin and Activin A** to **enhance muscle growth** and **improve quality of weight loss** during and after treatment with incretin drugs

Why Myostatin & Activin A

- Myostatin and Activin A are **key negative regulators** of muscle mass
- Both are members of the TGFβ superfamily
- Activin A mechanism is **pharmacologically validated**[1, 2]
- **Combined** Activin A and Myostatin **inhibition**, **causes** more **pronounced muscle growth**[3]
- Myostatin and Activin A inhibition are **key features for treating PH-HFpEF**

Binding of Myostatin and Activin A to cells leads to **muscle atrophy**



Simultaneous blocking of Myostatin and Activin A leads to **muscle growth**



1. Villanueva, J. et al. Am J Cardiovasc Drugs (2024).
2. US20220119514A1, Regeneron corporate slides
3. Latres, E. et al. Nat Commun 8, 15153 (2017).

iBio's Myostatin and Activin A Bi-Specific Targets Both Key Negative Muscle Regulators, Synergistically Increasing Muscle Mass

In Vitro Data

Only a Myostatin x Activin A bi-specific antibody fully blocks both muscle growth suppressors, enabling optimal growth, while single-target antibodies fall short

Increased muscle fusion index in human muscle stem cells is a surrogate of muscle growth




Technology Stack

Any Epitope on Any Drug Target

AI Epitope Engineering and Antibody Optimization Engines unlock challenging target classes

iBio's Discovery Engine

We use our Tech Stack to generate new IP against **hard-to-drug targets** – from **idea to Development Candidate** in **7 months**

iBio's Proprietary AI Technology Platform

- **Multi-layer technology platform** addresses multiple challenges in Ab discovery
- **Patented Epitope Steering** technology
- **Single-step Ab** StableHu™ x Mammalian Display
- **Masked** (ShieldTx®) Antibodies
- **T-cell engager panel** (EngageTx™)

AI-guided precision hits that are epitope class agnostic

- Selectively targets **functional epitopes**
- Epitopes with **complex modes of action**
- Unlocks **novel target** classes
- Accelerates discovery of Ab against **validated targets**

Generative AI meets mammalian display: Ab optimization in 3 weeks

- Gen AI creates **mammalian display** libraries with phage-like diversity
- Single-shot **multidimensional lead optimization**
- Compatible with **multi-specific** antibody formats
- Antibody **format agnostic**

Engineered Epitopes Are Tailor-Made Solutions to Target Any Epitope



Mammalian Display Enables Rapid Whole Molecule Optimization

Input library of diverse sequences, formats, masks, and linkers



Multi-dimensional cell sorting selects for high expression, positive on target binding, and negative off-target binding


Corporate Summary

A Leadership Team with Deep Industry Experience

Martin Brenner, DVM, Ph.D.
CEO & CSO

PFENEX
Lilly
MERCK
AstraZeneca
Pfizer
Recursion

Felipe Duran
CFO

LUPIN
teva
noven
Bupa

Marc Banjak
CLO

istari
Dova
ICON
B BRAUN
PPD

Kristi Sarno
Senior VP BD

HOMOLOGY
PFENEX
Latham
Crucell

Executive Summary



Corporate Highlights

Differentiated Pipeline Solving for the Challenges of today's GLP1's

- Quality weight loss (IBIO-600, IBIO-610)
- Developability (IBIO-600, IBIO-610)

Patented AI-Driven Discovery Tech Stack

- Rapidly advance a highly developable pre-clinical pipeline
- Solve hard-to-drug problems

Financial Highlights

- $10.5M in cash and restricted cash and cash equivalents as of May 1, 2025
- ~16.22M shares outstanding as of June 13, 2025


Appendix


Pre-Clinical
Immuno-Oncology
Pipeline
37

Beyond Cardiometabolic – Driving Value Within Our Oncology Pipeline

Program	MoA	Potential Indications	Early Discovery	Late Discovery	Lead Optimization	IND-Enabling	Highlights
IBIO-101	Treg depletion, IL-2 sparing	Solid tumors, orphan indications					Synergistic efficacy with checkpoint inhibitors
CCR8	Tumor-infiltrating Treg depletion	Solid tumors					Highly selective vs. closely related GPCRs
Trop-2 x CD3 ShieldTx EngageTx	Tumor-protease activated T cell engager	Solid tumors					ShieldTx technology enables masking; delivery as pro-drug activated in TME*
MUC16 x CD3 ShieldTx EngageTx	Tumor-protease activated T cell engager	Ovarian and pancreatic cancer					Binds membrane-proximal epitope, distinct from Regeneron MUC16xCD3
EGFRvIII	ADCC-enhanced Fc	Glioblastoma					Highly selective for EGFRvIII over EGFR
Latent TGFβ	Protein Complex Stabilization	Solid tumors					Innovative mechanism of action locking protein complex in inactive form

*Tumor Micro Environment


Technology
Stack
39

iBio's Tech Stack Aims to Solve Major Challenges in Antibody Discovery & Development

Epitope Steering

Unlocking Novel Biology

Pursuit of Elusive Targets
GPCRs, Ion Channels, Protein Complexes

Complex modalities
Agonistic Antibodies, Cell Activators, Protein Complex Stabilizers

Proprietary Naïve mAb Library

Improved Speed and Developability

Fully human Ab
Reduced immunogenicity risk by clinically validated Ab frameworks

Speed
Rapid hit ID vs immunization campaigns

Improved Developability
Known sequence liabilities eliminated

StableHu & Mammalian Display

Library Diversity
ML tools create focused diversity with smaller library size

Speed
Simultaneous, Multi-Dimensional Optimization

Improved Developability
Mammalian Display with production cell lines exclusively yields expressible clones

Optimized Antibody Leads

Reduced Lead-Optimization Time
Optimization in less than **4 weeks**

Minimized Developability Risk
Mammalian Display in Manufacturing Cell Line

Potential for Improved Safety
Selective "on-tissue" action of masked antibodies

First in Class Antibodies and / or Best in Class Antibodies

iBio's Tech Stack Addresses Immuno-oncology Discovery and Development Challenges

EngageTx

2nd Gen T-cell Engager Panel

Sequence Diversity
Increased humanness and broad CD3 activity for optimized pairing with antigen arms

Hu-Cyno Cross Reactivity
Risk reduction via cyno monkey toxicity study compatibility

Range of Cytokine Release
Tailored cytokine release for expanded therapeutic window

ShieldTx

Greater Safety With Tissue Specificity

Seamlessly Integrated Ab Masking
Engineered epitopes serve dual purpose for raising and masking of Abs

Flexibility in Candidate Selection
Simultaneous co-optimization of Ab, mask and linker provides maximized flexibility in candidate selection

Enhanced Efficacy and Safety of I/O Antibody Leads

Finely tuned T-cell engagement
Adjustable T-cell engagement to fit any tumor target engager

Improved safety prediction
Cyno cross reactivity allows for better preclinical safety assessment

Improved Safety Profile
Tissue selective action through "smart", conditionally activated, antibodies

Accelerate Success: StableHu Antibody Optimization & Mammalian Display Screening Propel Faster, Cost-Effective Antibody Development



"Smart" Antibodies: ShieldTx Conditionally Activated Antibodies Strive to Improve Safety by Selectively Targeting Diseased but not Healthy Tissue



EngageTx, a CD3-Based T-Cell Engager Panel, Addresses 3 Key Challenges: Cytokine Release, NHP Cross-Reactivity and Immunogenicity Risk

1 Sequence Diversity

Increased humanness and broad CD3 activity for optimized paring with tumor antigen arms



2 Hu-Cyno Cross-Reactivity

Risk reduction via cyno monkey toxicity study compatibility



3 Range of Cytokine Release

Tailored cytokine release for expanded therapeutic window



iBio's Platform Tackles Discovery Challenges for the Next Era of Antibodies



* U.S. Patent No. 11,545,238 (issued January 3, 2023)